Diseases and Drugs


beware-jun12.jpg Everyone dreads catching a viral infection. The word "virus" has its origin in Latin, which means slimy liquid or poison, and it has been associated with a number of disease outbreaks, epidemic, and pandemic. Now, let's take a look at some of the viruses that are posing a constant threat to mankind.

fdaapproval-march25.jpg Spinal muscular atrophy or SMA is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.

orofacialpain-jun07.jpg The sensation of pain is an unpleasant feeling. It is a signal sent out by the central nervous system, warning the body that something is wrong. According to the American Association of Neurological Surgeons, the disorder associated with the most excruciating pain known to humanity is trigeminal neuralgia, also known as tic douloureux.

fragmin-052419.jpg As another month comes to a close, it's time to take a look back at some of the pharma news stories of May, and look ahead at what's coming next over the horizon on the regulatory front.

fdaapproval-march25.jpg A disease that affected 9 countries in the world a few decades ago, dengue has now become endemic, affecting nearly half of the global population.

collage-april26.jpg A lot happened in the month of April, from the resignation of FDA Commissioner Scott Gottlieb coming into effect to the launch of the world's first malaria vaccine. Now, let's take a look at the companies that await a ruling from the FDA in May 2019.

fdaapproval-march25.jpg On April 8, the FDA approved Dovato, a two-drug regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.

anaptysbio-april12.jpg Peanut allergy, a condition in which the immune system mistakenly recognizes a number of proteins from peanuts as potential foreign pathogens, triggering an inflammation, is most common in children. The rate of peanut allergy is on the rise - with approximately 2 percent of children, roughly 1.5 million children in the U.S., being affected, according to the Jaffe Food Allergy Institute.

customersurprised-april03.jpg It typically takes 10-12 years to introduce a new drug into the market - i.e., from the initial discovery stage to regulatory approval - and it costs the drugmakers an average of $2.6 billion.

fda-march26.jpg So far this year, 4 novel drugs have been approved in the U.S., including Zulresso. Now, let's take a look at the companies that await a ruling from the FDA in April 2019.

fdaapproval-march25.jpg Postpartum depression, or PPD, is a mood disorder that can affect women after childbirth. In the U.s., estimates of new mothers identified with PPD each year vary by state from eitht to 20/%, with an overall average of 11.5%.

alzheimer-march01.jpg Alzheimer's is the 6th leading cause of death in the U.S., and there is no cure yet for this neurodegenerative disease. The available medications for Alzheimer's can only alleviate symptoms temporarily, and they don't work for everyone.

fda-feb26.jpg After a banner year in 2018, the novel drug approval is off to an uncharacteristically slow start this year. No novel drug was approved in January while three were approved in February.

pharma-oct17.jpg In January, the FDA approved two drugs. One is a biosimilar for the treatment of breast cancer and the other is a nasal spray for migraine.

spectrum-feb12.jpg Non-alcoholic steatohepatitis, or NASH, which refers to liver inflammation due to fat buildup in the liver, is said to affect an estimated 16 million Americans. NASH is a more severe form of nonalcoholic fatty liver disease, or NAFLD. The incidence of NASH is on the rise, and even worrying is the fact that there are no approved treatments for the disease, yet.

Follow RTT